Validating MARK2 Gene Polymorphism as a Predictor of Response to Lithium Treatment in Bipolar Patients

Publisher: Pasteur Institute of Iran Country of Publication: Iran NLM ID: 9814853 Publication Model: Electronic Cited Medium: Internet ISSN: 2008-823X (Electronic) Linking ISSN: 1028852X NLM ISO Abbreviation: Iran Biomed J Subsets: MEDLINE

Original Publication: Tehran : Pasteur Institute of Iran

Polymorphism, Genetic*; Antidepressive Agents/*therapeutic use ; Antimanic Agents/*therapeutic use ; Bipolar Disorder/*genetics ; Lithium Compounds/*therapeutic use ; Protein Serine-Threonine Kinases/*genetics; Bipolar Disorder/drug therapy ; Genotype ; Humans ; Iran ; Protein Serine-Threonine Kinases/metabolism

Background: Lithium is a therapeutic option for the treatment of the acute phase of the bipolar disorder and long-term management of this disorder. However, it is estimated that 10 to 60% of patients do not properly response to this medication.
Methods: To investigate the role of MARK2 gene in response to lithium, we genotyped the MARK2 rs10792421 polymorphism in Iranian bipolar patients using amplification Refractory Mutation System-PCR.
Results: Results of this study showed a significant association of this polymorphism with response to lithium. The A allele was more frequent in the responder than the non-responder group and also in the semi- responder group compared to the non-responder group in the codominant model of analysis. AA and AG genotypes were more frequent in both the responder and semi-responder groups compared to the non-responder group in dominant model of analysis.
Conclusion: Based on the findings of the current study, the rs10792421 variant of MARK2 gene could be considered as a potential biomarker for predicting the treatment outcome of bipolar disorder type 1 in Iranian population.

Bipolar Disord. 2016 Feb;18(1):63-70. (PMID: 26876913)
Genomics Proteomics Bioinformatics. 2016 Oct;14(5):298-313. (PMID: 27729266)
World J Biol Psychiatry. 2020 Apr;21(4):317-324. (PMID: 29893160)
J Biol Chem. 2002 Mar 8;277(10):7713-9. (PMID: 11756416)
Nucleic Acids Res. 2012 Jan;40(Database issue):D930-4. (PMID: 22064851)
J Biol Chem. 2005 Dec 30;280(52):42715-22. (PMID: 16257959)
Lancet Neurol. 2013 Feb;12(2):207-16. (PMID: 23332364)
J Biol Chem. 2012 Mar 9;287(11):8174-86. (PMID: 22238344)
Br J Psychiatry. 2016 Feb;208(2):195-6. (PMID: 26541689)
ACS Chem Neurosci. 2014 Jun 18;5(6):443-50. (PMID: 24766396)
Front Cell Neurosci. 2017 Jun 16;11:163. (PMID: 28670267)
Front Neurosci. 2019 Mar 13;13:220. (PMID: 30930738)
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8745-50. (PMID: 10411946)
J Affect Disord. 2011 Mar;129(1-3):14-26. (PMID: 20538341)
Mol Cell Neurosci. 2016 Jun;73:63-83. (PMID: 26608002)
Am J Transl Res. 2020 May 15;12(5):1807-1823. (PMID: 32509178)
Arch Gen Psychiatry. 1991 Dec;48(12):1082-8. (PMID: 1845226)
Psychiatry Res. 2015 Mar 30;226(1):23-30. (PMID: 25618475)
Dev Neurobiol. 2011 Jun;71(6):483-94. (PMID: 21557502)
Biochemistry. 2009 Mar 10;48(9):2045-52. (PMID: 19152501)
Front Mol Neurosci. 2014 May 08;7:37. (PMID: 24847206)
Med J Aust. 1949 Sep 3;2(10):349-52. (PMID: 18142718)
Behav Pharmacol. 2010 Sep;21(5-6):473-92. (PMID: 20700048)
Int J Alzheimers Dis. 2011;2011:352805. (PMID: 21776376)
Psychol Bull. 2014 May;140(3):774-815. (PMID: 24417575)
World Psychiatry. 2013 Jun;12(2):92-8. (PMID: 23737408)
Bipolar Disord. 2009 Jun;11 Suppl 2:92-109. (PMID: 19538689)
Expert Rev Neurother. 2008 Dec;8(12):1879-91. (PMID: 19086882)
Cereb Cortex. 2009 Jul;19 Suppl 1:i42-8. (PMID: 19346270)
J Alzheimers Dis. 2015;48(2):403-10. (PMID: 26402004)
Ther Adv Psychopharmacol. 2018 Oct 16;8(12):349-363. (PMID: 30524703)
Mol Biol Cell. 2002 Nov;13(11):4013-28. (PMID: 12429843)
J Biol Chem. 2008 Jul 4;283(27):18873-82. (PMID: 18424437)
Trends Biochem Sci. 2009 Jul;34(7):332-42. (PMID: 19559622)
Psychiatry Res. 2016 Jul 30;241:315-22. (PMID: 27227701)
J Alzheimers Dis. 2016;51(3):815-25. (PMID: 26890770)
J Alzheimers Dis. 2011;24(4):739-49. (PMID: 21321394)
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1617-27. (PMID: 18538910)
Br J Psychiatry. 1994 Feb;164(2):149-52. (PMID: 8173817)
Front Mol Neurosci. 2012 Feb 20;5:14. (PMID: 22363263)
Neuromolecular Med. 2013 Sep;15(3):458-69. (PMID: 23666762)
Front Mol Neurosci. 2011 Nov 16;4:40. (PMID: 22110425)

Keywords: Biomarkers; Bipolar; Genotyping; Lithium

0 (Antidepressive Agents)
0 (Antimanic Agents)
0 (Lithium Compounds)
EC 2.7.1.- (MARK2 protein, human)
EC 2.7.11.1 (Protein Serine-Threonine Kinases)

Date Created: 20211226 Date Completed: 20220204 Latest Revision: 20220420

20240829

PMC8987413

10.52547/ibj.26.2.110

34953473